title: [Pentoxifylline].
abstract: Pentoxifylline (PTX), methylxanthine derivative and phosphodiesterase inhibitor, has been in use for more than 20 years (with minimal side effects) for the potent hemorrheologic properties and was recently discovered to have influence on function of some immune cells and production of cytokines. Human and animal studies have shown that PTX therapy results in a variety of physiologic changes at the cellular level, which may be important in treating a diverse group of human afflictions. Immune modulation includes increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte adhesion, decreased neutrophil degranulation and release of superoxides, decreased production of TNF-alpha and decreased NK cell activity. Potential medical uses of PTX are reviewed.
authors.affiliation: Klinika Chirurgii Urazowej i Ortopedii Instytutu Chirurgii, Szpital Kliniczny Wojskowej Akademii Medycznej w Lodzi.
authors.forename: P T
authors.initials: PT
authors.lastname: Paradowski
authors.forename: K
authors.initials: K
authors.lastname: Zeman
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000187:drug effects; D008103:Liver Cirrhosis / Q000188:drug therapy; D009504:Neutrophils / Q000187:drug effects; D010431:Pentoxifylline / Q000494:pharmacology* / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects
chemical_list: D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline
vernacular_title: Pentoksyfilina.